CA2114440C - Affinites de fixation differentielle et dosages de dissociation bases sur ces affinites - Google Patents

Affinites de fixation differentielle et dosages de dissociation bases sur ces affinites Download PDF

Info

Publication number: CA2114440C
Authority: CA; Canada
Prior art keywords: receptor; ligand; analyte; release; cotinine
Prior art date: 1991-07-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002114440A

Other languages

English (en)

Other versions

CA2114440A1 (fr

Inventor

Judith Fitzpatrick

Regina B. Lenda

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Serex Inc

Original Assignee

Serex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-29

Filing date

1992-07-29

Publication date

2005-11-15

1992-07-29 Application filed by Serex Inc filed Critical Serex Inc

1992-07-29 Priority claimed from PCT/US1992/006249 external-priority patent/WO1993003367A1/fr

1993-02-18 Publication of CA2114440A1 publication Critical patent/CA2114440A1/fr

2005-11-15 Application granted granted Critical

2005-11-15 Publication of CA2114440C publication Critical patent/CA2114440C/fr

2012-07-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000009739 binding Methods 0.000 title claims abstract description 92
230000027455 binding Effects 0.000 title claims abstract description 92
238000010494 dissociation reaction Methods 0.000 title claims abstract description 40
230000005593 dissociations Effects 0.000 title claims abstract description 38
238000003556 assay Methods 0.000 title abstract description 267
239000003446 ligand Substances 0.000 claims abstract description 292
239000012491 analyte Substances 0.000 claims abstract description 198
238000000034 method Methods 0.000 claims abstract description 87
229950006073 cotinine Drugs 0.000 claims description 170
102000005962 receptors Human genes 0.000 claims description 167
UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical group C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 claims description 154
UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 claims description 142
102000004190 Enzymes Human genes 0.000 claims description 93
108090000790 Enzymes Proteins 0.000 claims description 93
239000007790 solid phase Substances 0.000 claims description 42
238000001514 detection method Methods 0.000 claims description 29
GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 claims description 26
102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 25
108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 25
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 25
KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 claims description 24
239000004816 latex Substances 0.000 claims description 18
238000012360 testing method Methods 0.000 claims description 18
238000001042 affinity chromatography Methods 0.000 claims description 17
229920000126 latex Polymers 0.000 claims description 17
229960004242 dronabinol Drugs 0.000 claims description 15
CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 14
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 14
239000007787 solid Substances 0.000 claims description 12
239000002245 particle Substances 0.000 claims description 10
239000003451 thiazide diuretic agent Substances 0.000 claims description 8
125000001931 aliphatic group Chemical group 0.000 claims description 7
239000012634 fragment Substances 0.000 claims description 7
230000004048 modification Effects 0.000 claims description 7
238000012986 modification Methods 0.000 claims description 7
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 6
108020004707 nucleic acids Proteins 0.000 claims description 6
102000039446 nucleic acids Human genes 0.000 claims description 6
150000007523 nucleic acids Chemical group 0.000 claims description 6
108010001857 Cell Surface Receptors Proteins 0.000 claims description 5
239000002876 beta blocker Substances 0.000 claims description 5
229940097320 beta blocking agent Drugs 0.000 claims description 5
102000006240 membrane receptors Human genes 0.000 claims description 5
239000011324 bead Substances 0.000 claims description 4
210000004027 cell Anatomy 0.000 claims description 4
239000005081 chemiluminescent agent Substances 0.000 claims description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
238000011065 in-situ storage Methods 0.000 abstract 1
108020003175 receptors Proteins 0.000 description 133
229940088598 enzyme Drugs 0.000 description 107
230000000694 effects Effects 0.000 description 62
239000000203 mixture Substances 0.000 description 52
210000002700 urine Anatomy 0.000 description 49
239000000243 solution Substances 0.000 description 48
239000003153 chemical reaction reagent Substances 0.000 description 45
238000006243 chemical reaction Methods 0.000 description 44
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
239000000872 buffer Substances 0.000 description 34
238000011534 incubation Methods 0.000 description 30
108090000623 proteins and genes Proteins 0.000 description 30
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
239000006228 supernatant Substances 0.000 description 28
230000009260 cross reactivity Effects 0.000 description 27
238000002360 preparation method Methods 0.000 description 27
235000018102 proteins Nutrition 0.000 description 26
102000004169 proteins and genes Human genes 0.000 description 26
XOKCJXZZNAUIQN-DTWKUNHWSA-N trans-3-hydroxycotinine Chemical compound C1[C@@H](O)C(=O)N(C)[C@@H]1C1=CC=CN=C1 XOKCJXZZNAUIQN-DTWKUNHWSA-N 0.000 description 25
230000035945 sensitivity Effects 0.000 description 24
238000003018 immunoassay Methods 0.000 description 23
238000002835 absorbance Methods 0.000 description 22
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 22
239000002953 phosphate buffered saline Substances 0.000 description 22
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
239000011159 matrix material Substances 0.000 description 20
238000011084 recovery Methods 0.000 description 18
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 17
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 17
239000000499 gel Substances 0.000 description 17
239000000463 material Substances 0.000 description 17
239000012528 membrane Substances 0.000 description 17
239000007983 Tris buffer Substances 0.000 description 16
230000008859 change Effects 0.000 description 16
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 15
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 15
229950006238 nadide Drugs 0.000 description 15
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 14
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
238000002965 ELISA Methods 0.000 description 13
239000000758 substrate Substances 0.000 description 13
241000283973 Oryctolagus cuniculus Species 0.000 description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
229920002684 Sepharose Polymers 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
239000007791 liquid phase Substances 0.000 description 11
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 10
239000000427 antigen Substances 0.000 description 10
230000007423 decrease Effects 0.000 description 10
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
-1 sodium chloride Chemical class 0.000 description 10
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 9
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
102000014914 Carrier Proteins Human genes 0.000 description 9
108010078791 Carrier Proteins Proteins 0.000 description 9
102000011022 Chorionic Gonadotropin Human genes 0.000 description 9
108010062540 Chorionic Gonadotropin Proteins 0.000 description 9
241000208125 Nicotiana Species 0.000 description 9
235000002637 Nicotiana tabacum Nutrition 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
229940084986 human chorionic gonadotropin Drugs 0.000 description 9
125000005647 linker group Chemical group 0.000 description 9
238000002156 mixing Methods 0.000 description 9
239000011534 wash buffer Substances 0.000 description 9
XGCCBKJIKOMKRR-UHFFFAOYSA-N Hydroxy-cotinin Natural products CN1C(C(O)CC1=O)c1cccnc1 XGCCBKJIKOMKRR-UHFFFAOYSA-N 0.000 description 8
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
241001494479 Pecora Species 0.000 description 8
238000002820 assay format Methods 0.000 description 8
PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 description 8
238000005259 measurement Methods 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 7
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 7
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 7
101710088194 Dehydrogenase Proteins 0.000 description 7
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 description 7
230000008901 benefit Effects 0.000 description 7
230000002860 competitive effect Effects 0.000 description 7
PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 description 7
239000008363 phosphate buffer Substances 0.000 description 7
229920000136 polysorbate Polymers 0.000 description 7
210000003296 saliva Anatomy 0.000 description 7
229910000029 sodium carbonate Inorganic materials 0.000 description 7
229940014800 succinic anhydride Drugs 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000008103 glucose Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 6
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
102000013415 peroxidase activity proteins Human genes 0.000 description 6
108040007629 peroxidase activity proteins Proteins 0.000 description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
XOKCJXZZNAUIQN-IUCAKERBSA-N 3'-Hydroxycotinine, Cis- Chemical group C1[C@H](O)C(=O)N(C)[C@@H]1C1=CC=CN=C1 XOKCJXZZNAUIQN-IUCAKERBSA-N 0.000 description 5
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000001124 body fluid Anatomy 0.000 description 5
239000011521 glass Substances 0.000 description 5
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
239000000376 reactant Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
FXFANIORDKRCCA-UHFFFAOYSA-N Norcotinine Chemical compound N1C(=O)CCC1C1=CC=CN=C1 FXFANIORDKRCCA-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
229960004050 aminobenzoic acid Drugs 0.000 description 4
239000010839 body fluid Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
230000009918 complex formation Effects 0.000 description 4
239000000975 dye Substances 0.000 description 4
238000010828 elution Methods 0.000 description 4
108010074605 gamma-Globulins Proteins 0.000 description 4
229960002003 hydrochlorothiazide Drugs 0.000 description 4
229910001629 magnesium chloride Inorganic materials 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
239000004033 plastic Substances 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000006641 stabilisation Effects 0.000 description 4
238000011105 stabilization Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000011800 void material Substances 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
MNIQECRMTVGZBM-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC=N2.CN1CCCC1C1=CC=CN=C1 MNIQECRMTVGZBM-UHFFFAOYSA-N 0.000 description 3
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
229960002684 aminocaproic acid Drugs 0.000 description 3
239000012131 assay buffer Substances 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 3
238000012875 competitive assay Methods 0.000 description 3
239000000287 crude extract Substances 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
208000018459 dissociative disease Diseases 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000002359 drug metabolite Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
229940127121 immunoconjugate Drugs 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
229960002715 nicotine Drugs 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
238000003756 stirring Methods 0.000 description 3
230000007704 transition Effects 0.000 description 3
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
102000006771 Gonadotropins Human genes 0.000 description 2
108010086677 Gonadotropins Proteins 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
230000004308 accommodation Effects 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000009849 deactivation Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000000385 dialysis solution Substances 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
238000002875 fluorescence polarization Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
239000002622 gonadotropin Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000018791 negative regulation of catalytic activity Effects 0.000 description 2
238000010606 normalization Methods 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000005457 optimization Methods 0.000 description 2
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
230000005180 public health Effects 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
238000002764 solid phase assay Methods 0.000 description 2
241000894007 species Species 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
229950002929 trinitrophenol Drugs 0.000 description 2
DEYLVDCFTICBTB-WCBMZHEXSA-N (2s,3s)-1-methyl-5-oxo-2-pyridin-3-ylpyrrolidine-3-carboxylic acid Chemical compound OC(=O)[C@H]1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 DEYLVDCFTICBTB-WCBMZHEXSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical class CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 description 1
FEXBEKLLSUWSIM-UHFFFAOYSA-N 2-Butyl-4-methylphenol Chemical compound CCCCC1=CC(C)=CC=C1O FEXBEKLLSUWSIM-UHFFFAOYSA-N 0.000 description 1
FHYIWJUGJFNOHY-UHFFFAOYSA-N 3-(ethyliminomethylideneamino)propan-1-amine Chemical compound CCN=C=NCCCN FHYIWJUGJFNOHY-UHFFFAOYSA-N 0.000 description 1
CWEPACWBWIOYID-UHFFFAOYSA-N 4'-hydroxypropanolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=C(O)C2=C1 CWEPACWBWIOYID-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
AWUYFGAFMDHVRA-UHFFFAOYSA-N 5-oxo-1-propan-2-yl-2-pyridin-3-ylpyrrolidine-3-carboxylic acid Chemical compound OC(=O)C1CC(=O)N(C(C)C)C1C1=CC=CN=C1 AWUYFGAFMDHVRA-UHFFFAOYSA-N 0.000 description 1
ODJCRFJAWKSMBI-UHFFFAOYSA-N 5-oxo-1-propyl-2-pyridin-3-ylpyrrolidine-3-carboxylic acid Chemical compound OC(=O)C1CC(=O)N(CCC)C1C1=CC=CN=C1 ODJCRFJAWKSMBI-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000790646 Cotinis Species 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000688216 Homo sapiens Intestinal-type alkaline phosphatase Proteins 0.000 description 1
101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
102100034866 Kallikrein-6 Human genes 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000005565 Marijuana Use Diseases 0.000 description 1
HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000004451 Pituitary Gonadotropins Human genes 0.000 description 1
108010081865 Pituitary Gonadotropins Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
230000010757 Reduction Activity Effects 0.000 description 1
241000700605 Viruses Species 0.000 description 1
101000779569 Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4) Alkaline phosphatase PhoD Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
PUQIRTNPJRFRCZ-UHFFFAOYSA-N atenolol acid Chemical compound CC(C)NCC(O)COC1=CC=C(CC(O)=O)C=C1 PUQIRTNPJRFRCZ-UHFFFAOYSA-N 0.000 description 1
230000000386 athletic effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
231100000319 bleeding Toxicity 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
238000002967 competitive immunoassay Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000007357 dehydrogenase reaction Methods 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
QRGNQKGQENGQSE-WUEGHLCSSA-L disodium;[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [(2r,3s,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 QRGNQKGQENGQSE-WUEGHLCSSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
238000010799 enzyme reaction rate Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
238000005562 fading Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
230000001456 gonadotroph Effects 0.000 description 1
229940094892 gonadotropins Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000002117 illicit drug Substances 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
125000003010 ionic group Chemical group 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
WJKYOQDIQYJXSD-UHFFFAOYSA-N propan-1-imine Chemical compound CCC=N WJKYOQDIQYJXSD-UHFFFAOYSA-N 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000006965 reversible inhibition Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
238000002791 soaking Methods 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007306 turnover Effects 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000012224 working solution Substances 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Landscapes

Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA002114440A 1991-07-29 1992-07-29 Affinites de fixation differentielle et dosages de dissociation bases sur ces affinites Expired - Fee Related CA2114440C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73752691A	1991-07-29	1991-07-29
US737,526		1991-07-29
PCT/US1992/006249 WO1993003367A1 (fr)	1991-07-29	1992-07-29	Affinites de liaison differentielles et methodes de detection de dissociation basees sur ces affinites

Publications (2)

Publication Number	Publication Date
CA2114440A1 CA2114440A1 (fr)	1993-02-18
CA2114440C true CA2114440C (fr)	2005-11-15

Family

ID=35520879

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002114440A Expired - Fee Related CA2114440C (fr)	1991-07-29	1992-07-29	Affinites de fixation differentielle et dosages de dissociation bases sur ces affinites

Country Status (1)

Country	Link
CA (1)	CA2114440C (fr)

1992
- 1992-07-29 CA CA002114440A patent/CA2114440C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2114440A1 (fr)	1993-02-18

Legal Events

Date	Code	Title	Description
1999-07-26	EEER	Examination request
2009-07-29	MKLA	Lapsed

Publication	Publication Date	Title
US5527686A (en)	1996-06-18	Differential binding affinities and dissociation assays based thereon
US5168057A (en)	1992-12-01	Trifunctional conjugates
US5480792A (en)	1996-01-02	Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US4298685A (en)	1981-11-03	Diagnostic reagent
US4818687A (en)	1989-04-04	Affinity column and process for detection of low molecular weight toxic substances
US5710009A (en)	1998-01-20	Receptor:release ligand (reland) complexes and release assays using said reland and methods and kits based thereon
JPS63112599A (ja)	1988-05-17	免疫複合体レセプター
EP0640216B1 (fr)	2002-10-02	Technique de separation
WO1994003811A1 (fr)	1994-02-17	Detection immunologique au moyen de deux marqueurs detectables
CA2114440C (fr)	2005-11-15	Affinites de fixation differentielle et dosages de dissociation bases sur ces affinites
WO1997016727A1 (fr)	1997-05-09	Reduction de l'activite de fond pour un dosage, a l'aide de glycoproteines comportant des glucides oxydes
WO2007081868A9 (fr)	2007-09-07	Détermination de la concentration en fk778 au moyen d'un immunoessai compétitif
AU739280B2 (en)	2001-10-11	Receptor: release ligand (reland) complexes and assays and kits based thereon
Cernoch et al.	2011	Production and analytical characterization of neopterin immunoreagents for biosensor developments
Hallaj et al.	2003	A heterologous enzyme linked immunosorbant assay of morphine using penicillinase as label
EP0597034A1 (fr)	1994-05-18	Haptenes, traceurs, immunogenes et anticorps pour immunoanalyses de detection de propoxyphene
Rubenstein	1981	New Homogeneous Assay Methods for the Determination of Proteins
Ferenčík	1993	Immunochemical methods
GB2271634A (en)	1994-04-20	Assay comprising an immobilised additional auxiliary species
WO1994007140A1 (fr)	1994-03-31	Procede de separation